sumatriptan/naproxen / Generic mfg. - LARVOL DELTA

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group. (PubMed, Front Neurol) - "Fixed-dose sumatriptan/naproxen sodium was associated with modest 2-h pain freedom but clinically meaningful pain relief, functional recovery, and low rescue medication use. Tolerability was consistent with the known profiles of triptans and non-steroidal anti-inflammatory drugs."

HEOR • Journal • Real-world evidence • CNS Disorders • Fatigue • Migraine • Pain

Drug interventions for acute treatment of pediatric migraine: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "Sumatriptan/naproxen sodium, ibuprofen, zolmitriptan nasal spray, sumatriptan nasal spray, and rizatriptan showed statistical significance. Sumatriptan/naproxen sodium merits consideration, especially in patients exhibiting an inadequate response to monotherapy. Dihydroergotamine demonstrated potential benefits in refractory and chronic migraine; however, high-quality studies are warranted to validate these findings."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain • Pediatrics

i-NEED: NEw migrainE Drugs Database (clinicaltrials.gov) - P=N/A | N=2641 | Recruiting | Sponsor: IRCCS San Raffaele Roma | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • CNS Disorders • Migraine • Pain

Novel optimization of multi-mechanistic approaches for the acute treatment of a migraine attack: A review. (PubMed, Headache) - "Combination treatments with different mechanisms of action targeting key distinct pathophysiological processes of migraine may be more effective than monotherapies, particularly if their pharmacokinetic profiles are optimized to target those processes at the right time. Further research in this area is warranted."

Journal • Review • CNS Disorders • Migraine • Pain

Synergistic effects of H2O2, melatonin, and L-cysteine on biochemical traits and alkaloid accumulation in Catharanthus roseus L. "Ocellatus" in vitro plants. (PubMed, BMC Plant Biol) - "The results demonstrate that H in combination with MT or Cys differentially modulates redox balance and metabolic flux, enabling selective enhancement of antioxidant enzymes and valuable alkaloids. Optimized elicitor combinations therefore provide an effective strategy for targeted metabolic engineering of C. roseus under in vitro conditions."

Journal • Preclinical

Investigation of the pain reduction and migraineassociated symptoms in the treatment of migraine attack in a real-world setting of Austrian patients after the introduction of Sumatriptan 85mg/Naproxen-Natrium 500mg combination tablet (EHF-EHC 2025) - "Sumatriptan 85mg/Naproxen Natrium 500mg combination tablet was effective and generally well tolerated in the treatment of our patients presenting with migraine headaches. These data provide insights into real-word utilisation of the new combination tablet Sumatriptan 85mg/Naproxen Natrium 500mg in the treatment of acute migraine attacks."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Musculoskeletal Pain • Pain

Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans. (PubMed, Neurol Ther) - "The panel specifically considered the sumatriptan succinate-naproxen sodium combination, which was recently introduced in Europe and may be beneficial in patients not responding to NSAIDs, particularly for special patient groups, such as those with menstrual-related acute migraine or migraine attacks with prolonged pain or postdrome. Finally, the consensus highlights the need for individualized treatment plans and the importance of considering patient preferences and specific symptoms, integrating evidence-based recommendations with patient-centered care to optimize migraine management."

Journal • Review • CNS Disorders • Migraine • Pain

Galcanezumab-gnlm as an Effective Treatment for Chronic Migraine: A Case Report. (IHC 2025) - "Previous acute treatments included Neosaldina, Tramadol, Rizatriptan, SUMAXPRO (Sumatriptan + Naproxen), Dimenhydrinate, and Bromazepam. Preventive treatments included nortriptyline, cannabidiol, topiramate (200 mg/day, causing cognitive side effects such as memory lapses and difficulty completing sentences), and two cycles of OnabotulinumtoxinA (Botox), which provided temporary relief (15 and 7 days, respectively)...Monthly injections were maintained. Conclusion This case supports the efficacy and tolerability of galcanezumab-gnlm in a patient with chronic, treatment-resistant migraine, highlighting its value as a preventive therapeutic option."

Case report • Clinical • CNS Disorders • Migraine

Perceptions and Willingness to Use Acute Treatments Among Individuals With Migraine: Cross-Sectional Analysis in Argentina (IHC 2025) - "Price disclosure significantly increased willingness for diclofenac potassium (+0.70; 95% CI: 0.42–0.98; p < 0.001), sumatriptan (+0.43; 95% CI: 0.13–0.73; p = 0.001), ergotamine + caffeine (+0.55; 95% CI: 0.32–0.77; p < 0.001), dipyrone (+0.41; 95% CI: 0.24–0.59; p < 0.001), and aspirin (+0.44; 95% CI: 0.20–0.67; p < 0.001). Willingness significantly decreased for rimegepant (–0.74; 95% CI: –0.96 to –0.52; p < 0.001), sumatriptan + naproxen (–0.60; 95% CI: –0.92 to –0.27; p < 0.001), and aspirin + caffeine + paracetamol (–0.35; 95% CI: –0.57 to –0.12; p = 0.003)... Willingness to use acute migraine medications is influenced by the efficacy, adverse effects, and price. Nevertheless, costs significantly modify willingness over efficacy and security. As integrating patient preferences and economic considerations into migraine treatment decisions will lead to better outcomes, this study provides a new poin of view into patient preferences in Argentina and..."

Clinical • Late-breaking abstract • CNS Disorders • Migraine

i-NEED: NEw migrainE Drugs Database (clinicaltrials.gov) - P=N/A | N=2641 | Recruiting | Sponsor: IRCCS San Raffaele Roma

New trial • CNS Disorders • Migraine • Pain

sumatriptan 85mg / naproxen 457mg (Suvexx) is not recommended for use within NHSScotland (Scottish Medicines Consortium) - "Indication under review: the acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient. Suvexx offers a combination tablet of sumatriptan and naproxen. It is available at a considerable cost premium to sumatriptan 100mg and naproxen 500mg tablets taken separately."

Reimbursement • Migraine • Pain

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

SMART: Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: IRCCS San Raffaele Roma

HEOR • New trial • Real-world evidence • CNS Disorders • Migraine • Pain

Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Completed | Sponsor: Mayo Clinic | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • CNS Disorders • Migraine • Pain

Sumatriptan-naproxen sodium in migraine: A review. (PubMed, Eur J Neurol) - "Multi-mechanistic therapeutic agents offer an opportunity to optimise acute medications by targeting multiple mediators involved in the pathogenesis of migraine. Sumatriptan-naproxen sodium resulted in greater initial and sustained pain freedom, compared with either sumatriptan, naproxen-sodium and/or placebo, for the treatment of single or multiple attacks of migraine across both adult and adolescent study populations."

Journal • Review • CNS Disorders • Migraine • Pain

SK chemicals launches 1st combo migraine treatment in Korea (Korea Biomedical Review) - "SK chemicals said it launched the first combination migraine treatment, Suvexx, in Korea. The drug combines two active ingredients—sumatriptan, a triptan commonly used for migraine relief, and naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID)."

Launch non-US • CNS Disorders • Migraine • Pain

Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Aug 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Migraine • Pain

Sumatriptan-naproxen sodium fix-dose combination for acute migraine treatment, a review (PubMed, Ideggyogy Sz) - "Furthermore the combination showed beneficial effect on accompanying symptoms of migraine attack (i.e. nausea, photo- and phonophobia). Adverse events were mild or moderate in severity and rarely led to withdrawal of the drug.It can be concluded that sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination is effective, safe and well-tolerated in the acute treatment of migraine. ."

Clinical • Journal • Review • CNS Disorders • Migraine • Pain

Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Aug 2023 ➔ Dec 2023 | Trial primary completion date: Mar 2023 ➔ Aug 2023

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Migraine • Pain

Searchlight Pharma Announces Suvexx Launch in Europe, along with Deal Expansion to all E.U. Markets (Businesswire) - "Searchlight Pharma Inc...today announced that Orion Corporation...has launched Suvexx® in select countries covered in the 2020 exclusive license and supply agreement (the 'License Agreement') between Nuvo Pharmaceuticals (Ireland) DAC ('Nuvo Ireland') and Orion, with the product launches continuing into 2024....Nuvo Ireland and Orion have also entered into an amendment to the original License Agreement for the exclusive right to package, distribute, market and sell Suvexx in all remaining E.U. countries outside of the original License Agreement Territory. Orion anticipates filing the marketing authorization application immediately and expects to commercially launch Suvexx in Austria, Belgium, the Czech Republic, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Slovakia, Spain, Switzerland and the U.K. during 2024, subject to receipt of marketing authorization and pricing approval."

Launch Europe • Licensing / partnership • CNS Disorders • Migraine • Pain

Drugs for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine: A Systematic Review. (PubMed, Indian Pediatr) - "We found that rizatriptan (good tolerability profile with a dose of 5 mg) and sumatriptan (oral administration) had higher efficiency as compared to other triptans. Regardless of type or dose, all triptans are generally well tolerated by patients, but a few adverse effects such as light-headedness (sumatriptan), nasopharyngitis, and, muscular spasms (sumatriptan/ naproxen), somnolence, and dry mouth (rizatriptan), and dizziness (zolmitriptan group) were reported with the triptans."

Journal • Review • CNS Disorders • Infectious Disease • Migraine • Pain • Pediatrics • Xerostomia

Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Active, not recruiting | Sponsor: Mayo Clinic

New trial • Cardiovascular • CNS Disorders • Migraine • Pain

Miravo Healthcare Enters into Definitive Agreement to be Acquired by Searchlight Pharma Inc. (Businesswire) - "Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare...and Searchlight Pharma Inc., a private Canadian-based specialty healthcare company...are pleased to announce that they have entered into a definitive agreement (the 'Arrangement Agreement') pursuant to which the Purchaser has agreed to acquire all of the issued and outstanding common shares of the Company (the 'Company Shares') in exchange for cash consideration of $1.35 per Company Share, representing a 79.8% premium to the 90-day volume-weighted average trading price of the Company Shares on the Toronto Stock Exchange for the period ended December 22, 2022....'Not only does an all-cash transaction provide immediate and certain value to shareholders, it also allows important healthcare products like...Cambia® and Suvexx® to remain available to healthcare providers and patients through the enhanced scale of the Searchlight business.'"

M&A • CNS Disorders • Migraine • Pain